IRVINE, Calif.--(BUSINESS WIRE)--

BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today it will be previewing Epic Pro™, an all-new, innovative dental diode laser system at the upcoming Greater New York Dental Meeting to be held November 25-30 at the Jacob Javits Convention Center in New York City.

The Epic Pro, which offers the most laser power of any diode laser in dentistry, is the first product to be introduced resulting from BIOLASE’s strategic development agreement with IPG Photonics. The newest addition to the Epic family of dental soft-tissue lasers, Epic Pro features several new innovations that are industry-firsts:

• A new super pulse technology for more precise, enhanced laser tissue cutting;
• Real-time automatic power control to enhance speed and consistency when performing surgery;
• Pre-initiated, bendable, disposable tips with new smart tip technology to ensure tip performance and quality.

The new systems will provide even more predictable, minimally-invasive solutions for soft-tissue management than are currently offered by its market-leading Epic X product and other diode lasers on the market. It represents the first premium grade diode laser from BIOLASE and an important example of the kind of innovation BIOLASE is working on, both with IPG and through its internal product development efforts, noted BIOLASE President and CEO Harold C. Flynn, Jr.

“The introduction of Epic Pro is an important milestone for our company. We are proud to be expanding our diode laser range to incorporate new innovations that will allow dental professionals to manage soft tissue with lasers in a way that no other diode laser has achieved,” Flynn said. “Epic Pro represents our ongoing commitment to elevating the standard of care in dentistry, and achieving better patient reported outcomes while enabling clinicians to realize better business returns. We are very excited about the possibilities offered to our customers by this new technology addition to our portfolio.”

The Epic Pro laser system is currently undergoing premarket notification review by FDA for dental / surgical operations, intended for use in contact and non-contact techniques for incision, excision, vaporization, ablation, hemostasis, or coagulation of intraoral and extra-oral soft tissue (including marginal and interdental gingiva and epithelial lining of free gingiva). It is not yet available for sale within the United States.

Visit the BIOLASE booth #422 at the Greater New York Dental Meeting to preview this latest breakthrough in soft-tissue laser technology.

About BIOLASE, Inc.

BIOLASE, Inc. is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine and also markets, sells, and distributes dental imaging equipment, including digital x-rays and CAD/CAM scanners. BIOLASE’s products are focused on technologies that advance the practice of dentistry to both dentists and their patients. BIOLASE's proprietary laser products incorporate approximately 255 patented and 90 patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. Its innovative products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold approximately 32,800 laser systems to date in over 90 countries around the world. Laser products under development address BIOLASE’s core dental market and other adjacent medical and consumer markets.

For updates and information on Waterlase® iPlus™ and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, LinkedIn at www.linkedin.com/company/biolase, Instagram at www.instagram.com/biolaseinc, and YouTube at www.youtube.com/biolasevideos.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Statements contained in this press release that refer to BIOLASE's estimated or anticipated future results or other non-historical facts are forward-looking statements, as are any statements in this press release concerning prospects related to BIOLASE's strategic initiatives and anticipated financial performance. Forward-looking statements can also be identified through the use of words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “will,” and variations of these words or similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current expectations regarding existing trends, our strategic initiatives, the closing of the private placement and expected use of proceeds and speak only as of the date of this release. Actual results may differ materially from BIOLASE’s current expectations depending upon a number of factors affecting BIOLASE’s business. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that may be detailed, from time-to-time, in BIOLASE's reports filed with the SEC. BIOLASE does not undertake any responsibility to revise or update any forward-looking statements contained herein.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161122005418/en/